On Aug. 30, 2024, the California Institute for Regenerative Medicine (CIRM) approved $67.5 million to support five projects in the Agency’s pilot ReMIND (Research using Multidisciplinary, Innovative Approaches in Neuro Diseases) Program to support research in Autism Spectrum Disorder (ID/ASD) and schizophrenia.

ReMIND is an initiative designed to accelerate the discovery of mechanisms underlying neuropsychiatric disorders leading to the identification and validation of novel targets and biomarkers. The awards correspond to the first, DISC4/ReMIND-L that has been designed to support large collaborative multidisciplinary projects cross-disciplinary, and integrated studies led by large collaborative teams applying a range of technologies and approaches.